January 19th, 2012
Are We Ready to Stop Treating Cholesterol Levels and Start Treating Risk?
Harlan M. Krumholz, MD, SM
With the advent of ATPIV, should we stick with determining treatment based on LDL levels or is time for a new paradigm based on a more nuanced understanding of risk?
NEJM Journal Watch — Recent Cardiology Articles- Strategies and Criteria for the Diagnosis and Management of Myocarditis
- Sex-Based Disparity in CABG Outcomes: Are We Moving Toward Parity?
- Can Genetic and Social Risk Scores Improve Cardiac Risk Prediction?
- Extensive Ablation vs. Pulmonary Vein Isolation in Persistent Atrial Fibrillation
- Can a Novel Stent Design Improve Long-Term Outcomes of Percutaneous Coronary Intervention?